Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes

[1]  C. Polanczyk,et al.  ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores , 2021, International Journal of Infectious Diseases.

[2]  C. Polanczyk,et al.  Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry , 2021, International Journal of Infectious Diseases.

[3]  G. Remuzzi,et al.  Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 , 2020, Nature Reviews Nephrology.

[4]  G. Koh.  Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[5]  F. Castelli,et al.  Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia , 2020, Infection.

[6]  C. Morillo,et al.  COVID-19: Implications for People with Chagas Disease , 2020, Global heart.

[7]  D. Peaper,et al.  Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19 , 2020, The American journal of tropical medicine and hygiene.

[8]  Jordan J. Clark,et al.  Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[9]  L. Azevedo,et al.  Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology , 2020, Revista Brasileira de terapia intensiva.

[10]  L. Cooper,et al.  Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management , 2020, Heart Rhythm.

[11]  P. Chan,et al.  Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression , 2020, The Journal of antimicrobial chemotherapy.

[12]  F. Crea,et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options , 2020, Cardiovascular research.

[13]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[14]  Q. Tong,et al.  COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression , 2020, The Journal of antimicrobial chemotherapy.

[15]  Xiang Xie,et al.  COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.

[16]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[17]  Guillermo J. Lagos-Grisales,et al.  Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.

[18]  K. Gómez,et al.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease , 2018, Front. Immunol..

[19]  I. Molina,et al.  Chagas disease , 2018, The Lancet.

[20]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[21]  J. Muñoz,et al.  Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response , 2016, PLoS neglected tropical diseases.

[22]  I. Molina,et al.  Immunosuppression and Chagas disease; experience from a non-endemic country. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Chagas disease in Latin America: an epidemiological update based on 2010 estimates. , 2015, Releve epidemiologique hebdomadaire.

[24]  Petra Kendall-Raynor,et al.  The management challenge. , 2013, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[25]  G. Espinosa,et al.  Immunosuppression and Chagas Disease: A Management Challenge , 2013, PLoS neglected tropical diseases.

[26]  J. Sekhon,et al.  Genetic Matching for Estimating Causal Effects: A General Multivariate Matching Method for Achieving Balance in Observational Studies , 2006, Review of Economics and Statistics.

[27]  Clareci Silva Cardoso,et al.  Cost-benefit of the telecardiology service in the state of Minas Gerais: Minas Telecardio Project. , 2011, Arquivos brasileiros de cardiologia.

[28]  J. Marin-Neto,et al.  I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy , 2011 .

[29]  J. Coura,et al.  Chagas disease: a new worldwide challenge , 2010, Nature.

[30]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[31]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[32]  Douglas G Altman,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.

[33]  S. Pocock,et al.  Guidelines for Reporting Observational Studies , 2007 .

[34]  R. Isturiz,et al.  Chagas Disease , 2021, Neglected Tropical Diseases.

[35]  Robert C. Wolpert,et al.  A Review of the , 1985 .